Company Current Liabilities: Wave Pharma (WVE)

Symbol and logo of brand Wave Pharma (WVE)

Wave Life Sciences (WVE) is seeing its competitive advantage grow due to successful tests of drugs based on the PRISM system and unique patents, which the asset value tracked on the GURU.Markets chart confirms at 0.01. The business relies on developing treatments for rare pathologies with long-term monetization of formulas, while operational stability is maintained through diversified raw material supplies for RNA products.

WVE (Wave Life Sciences Ltd) Short-Term Debt history from 07/04/2022 to 10/30/2026

Wave Pharma - analytical breakdowns and key metrics (WVE)

- stock price and consensus target price:
Stock Price Wave Life Sciences Ltd.|WVE - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Valuation Wave Life Sciences Ltd.|WVE - Total Company Value
- balance sheet net asset value indicators:
Book Value per Share Wave Life Sciences|WVE - Total Stockholders' Equity|Market Cap to Net Assets Ratio wavelifesciences.com|WVE - Aggregate Asset Value
- company total debt and liquidity indicators:
Debt to Equity Wave Life Sciences|WVE - Long-Term Debt to Equity|Short-Term Debt to Capital Wave Life Sciences|WVE - Company Total Debt Obligations|Debts to Book Capitalization Wave Life Sciences Ltd.|WVE - Long-Term Liabilities|Company Short-Term Debts Wave Life Sciences|Quick Liquidity Indicator wavelifesciences.com
- net income and valuation multiples indicators:
WVE - Final Profit
Fundamental company analysis:Wave Life Sciences Ltd. (WVE)
Mass-produced product of Wave Pharma

The investment attractiveness of Wave Life Sciences (WVE) depends on the balance between R&D expenditures and financial stability. This metric aggregates all liabilities maturing within one year, reflecting the issuer's immediate liquidity. By analyzing the company's short-term liabilities, an investor assesses the business's ability to service debt amid geopolitical disruptions in raw material supplies. A downward trend confirms solvency but may indicate credit limits. This is a critical marker for capital preservation.

Key competitors

Tempus AI, Inc - Company Short-Term Debts|QGEN - Company Short-Term Debts|IONS (Ionis Pharma) - Company Current Liabilities|RGEN (Repligen Inc.) - Company Short-Term Debt|RNA (Avidity Biosciences) - Company Short-Term Debts|Short-Term Debt crisprtx.com CRSP|Company Current Liabilities WGS (GeneDx)|RARE (Ultragenyx Pharmaceutical Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Beam Therapeutics Corp BEAM|Sarepta Corp - Company Short-Term Debt|Twist Bioscience - Company Short-Term Debts|Short-Term Debt Volume 10xgenomics.com TXG|NTLA: Company Short-Term Debts|Current Liabilities STOK (Stoke Therapeutics Inc)|BLFS (BioLife Corp) - Company Short-Term Debts|Short-Term Debt Maze Therapeutics Corp MAZE|Company Current Liabilities SION (Sionna Therapeutics Inc)|PRME (primemedicine.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Taysha Gene Therapies, Inc. TSHA|Short-Term Debt Volume uniQure NV (QURE)|MeiraGTx PLC - Company Short-Term Debts|REGENXBIO Corp (RGNX) - Company Current Liabilities|SLDB: Company Short-Term Debts|OCGN - Short-Term Debt Volume|PACB (PacBio) - Company Short-Term Debts|Short-Term Debt Benitec Biopharma Inc BNTC|Company Short-Term Debt Design Pharma (DSGN)|Rocket Corp - Company Short-Term Indebtedness|Company Short-Term Debts FDMT (4D Molecular Therapeutics)|LXEO - Company Current Liabilities|Korro Bio, Inc - Company Short-Term Debts|Short-Term Debt Editas Medicine Inc|Silence Therapeutics Inc. (SLN) - Company Short-Term Debt|PRQR - Short-Term Debt Volume|Company Current Liabilities CDXS|Company Current Liabilities sangamo.com (SGMO)|Company Current Liabilities NAUT (Nautilus Biotechnology)|Company Short-Term Debt MGX (Metagenomi Inc.)|Company Short-Term Debts DTIL (Precision BioSciences)|Generation Bio Co (GBIO) - Short-Term Debt|Boundless Bio, Inc. - Company Short-Term Debts|XCUR (Exicure, Inc.) - Company Short-Term Indebtedness|imunon.com (IMNN) - Company Short-Term Debt|Company Short-Term Indebtedness PHIO|MBIO (Mustang Bio Inc) - Company Short-Term Debts|Company Short-Term Debts TransCode|Company Current Liabilities BNGO (Bionano Genomics, Inc.)|Company Current Liabilities adnas.com APDN|Company Short-Term Debts BLUE (bluebird bio)|Company Short-Term Debts ImmunoPrecise Antibodies Ltd IPA|OMGA: Company Current Liabilities|OMIC: Company Short-Term Debt|RGLS: Company Short-Term Debts|Short-Term Debt syros.com (SYRS)|Company Current Liabilities TBIO|TCON: Company Short-Term Loans and Borrowings|Company Short-Term Debt Unity Bio (UBX)